https://thescriptpad.com/articles/nicotinamide-riboside-early-parkinson-jama-trial.htmlThe Script Paden2026-10-13T09:30:00-04:00Nicotinamide Riboside Did Not Slow Early Parkinson Disease in a 410-Patient JAMA Trial. Scores Were Slightly Worse. https://thescriptpad.com/articles/medicaid-noncitizen-eligibility-changes-oct-1.htmlThe Script Paden2026-10-13T09:20:00-04:00Federal Funding for Full Medicaid Ended Oct. 1 for Refugees, Asylees and Other Lawfully Present Noncitizens. Check Your Denials. https://thescriptpad.com/articles/ama-report-pbm-market-concentration-75-percent.htmlThe Script Paden2026-10-13T09:10:00-04:00Four PBMs Now Manage 75 Percent of the Market, an AMA Report Finds. It Shows Concentration, Not Prices. https://thescriptpad.com/articles/hhs-vaccine-injury-reporting-medicare-code-gadv1.htmlThe Script Paden2026-10-12T09:30:00-04:00HHS Wants to Pay Physicians for Vaccine Injury Reports. Here Is the Medicare Code Already on the Table. https://thescriptpad.com/articles/two-esr1-approvals-two-testing-schedules.htmlThe Script Paden2026-10-12T09:25:00-04:00Two ESR1 Approvals in Two Weeks Set Two Different Testing Schedules. The Evidence Behind Each Is Not the Same. https://thescriptpad.com/articles/fda-warning-letter-ai-update-new-510k-virtuost-vfa.htmlThe Script Paden2026-10-12T09:20:00-04:00An FDA Warning Letter Says a New AI Model or a Move to the Web Can Require a New 510(k). Ask Your Vendors What Changed. https://thescriptpad.com/articles/fda-approves-weltruza-monthly-subcutaneous-olanzapine.htmlThe Script Paden2026-10-12T09:15:00-04:00FDA Approves Once-Monthly Subcutaneous Olanzapine (Weltruza) for Schizophrenia https://thescriptpad.com/articles/fda-advisory-committee-low-dose-atropine-myopia-oct-30.htmlThe Script Paden2026-10-12T09:10:00-04:00FDA Advisers Meet Oct. 30 on Low-Dose Atropine for Childhood Myopia. The Agency Declined to Approve It Last Year. https://thescriptpad.com/articles/fda-generative-ai-devices-comments-close-oct-19.htmlThe Script Paden2026-10-12T09:00:00-04:00FDA Wants Clinician Feedback on How to Regulate Generative AI Devices. Comments Close Oct. 19. https://thescriptpad.com/articles/fda-approves-lirafugratinib-fgfr2-cholangiocarcinoma.htmlThe Script Paden2026-10-12T08:55:00-04:00FDA Approves Lirafugratinib for Previously Treated FGFR2-Rearranged Cholangiocarcinoma. The Evidence Is a Single-Arm Trial. https://thescriptpad.com/articles/fda-draft-guidance-robotically-assisted-surgical-devices.htmlThe Script Paden2026-10-12T08:50:00-04:00FDA Has Drafted What It Wants to See Before Clearing a Surgical Robot. Comments Close Nov. 24. https://thescriptpad.com/articles/fda-adds-boxed-warning-injectafer-low-phosphate.htmlThe Script Paden2026-10-12T08:45:00-04:00FDA Adds a Boxed Warning to Injectafer for Low Phosphate Levels. Check How Your Infusion Protocols Handle It. https://thescriptpad.com/articles/medicare-2027-fee-schedule-conversion-factor-g2211-modifier.htmlThe Script Paden2026-10-11T09:30:00-04:00Medicare's 2027 Fee Schedule Would Cut the Conversion Factor and Turn G2211 Into a Percentage Modifier. Model It Before the Final Rule.